These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 17262995

  • 1. The protease inhibitor, Bowman-Birk Inhibitor, suppresses experimental autoimmune encephalomyelitis: a potential oral therapy for multiple sclerosis.
    Gran B, Tabibzadeh N, Martin A, Ventura ES, Ware JH, Zhang GX, Parr JL, Kennedy AR, Rostami AM.
    Mult Scler; 2006 Dec; 12(6):688-97. PubMed ID: 17262995
    [Abstract] [Full Text] [Related]

  • 2. Bowman-Birk inhibitor suppresses autoimmune inflammation and neuronal loss in a mouse model of multiple sclerosis.
    Touil T, Ciric B, Ventura E, Shindler KS, Gran B, Rostami A.
    J Neurol Sci; 2008 Aug 15; 271(1-2):191-202. PubMed ID: 18544456
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Interleukin-10 plays a crucial role in suppression of experimental autoimmune encephalomyelitis by Bowman-Birk inhibitor.
    Dai H, Ciric B, Zhang GX, Rostami A.
    J Neuroimmunol; 2012 Apr 15; 245(1-2):1-7. PubMed ID: 22365083
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of the Bowman-Birk inhibitor on clonogenic survival and cisplatin- or radiation-induced cytotoxicity in human breast, cervical, and head and neck cancer cells.
    Zhang L, Wan XS, Donahue JJ, Ware JH, Kennedy AR.
    Nutr Cancer; 1999 Apr 15; 33(2):165-73. PubMed ID: 10368812
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Bowman-Birk inhibitor concentrate suppresses experimental autoimmune neuritis via shifting macrophages from M1 to M2 subtype.
    Jin T, Yu H, Wang D, Zhang H, Zhang B, Quezada HC, Zhu J, Zhu W.
    Immunol Lett; 2016 Mar 15; 171():15-25. PubMed ID: 26791957
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effects of Bowman-Birk inhibitor on rat colon carcinogenesis.
    Kennedy AR, Billings PC, Wan XS, Newberne PM.
    Nutr Cancer; 2002 Mar 15; 43(2):174-86. PubMed ID: 12588698
    [Abstract] [Full Text] [Related]

  • 13. Effects of the Bowman-Birk inhibitor on growth, invasion, and clonogenic survival of human prostate epithelial cells and prostate cancer cells.
    Kennedy AR, Wan XS.
    Prostate; 2002 Feb 01; 50(2):125-33. PubMed ID: 11816021
    [Abstract] [Full Text] [Related]

  • 14. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial.
    Armstrong WB, Kennedy AR, Wan XS, Taylor TH, Nguyen QA, Jensen J, Thompson W, Lagerberg W, Meyskens FL.
    Clin Cancer Res; 2000 Dec 01; 6(12):4684-91. PubMed ID: 11156220
    [Abstract] [Full Text] [Related]

  • 15. Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia.
    Armstrong WB, Kennedy AR, Wan XS, Atiba J, McLaren CE, Meyskens FL.
    Cancer Epidemiol Biomarkers Prev; 2000 Jan 01; 9(1):43-7. PubMed ID: 10667462
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.